"Real-World" Survival for Renal Cell Carcinoma Patients Improving

Share this content:
A population-based study found survival benefit for metastatic renal cell carcinoma correlated with shift from cytokines to targeted therapies.
A population-based study found survival benefit for metastatic renal cell carcinoma correlated with shift from cytokines to targeted therapies.

Researchers who studied a population-based cohort of patients with metastatic renal cell carcinoma (mRCC) found a trend toward improved survival with the shift from the cytokine to the targeted therapy era. The degree of improvement, however, was slightly less than that observed in clinical trials of targeted therapies.

For non-clear-cell mRCC, the limited therapeutic options translated into modest survival gains in the targeted therapy era, according to the investigators.1

“These data permit accurate counseling of a heterogeneous, ‘real world' population of mRCC patients seeking care, especially in the setting of late presentation and unclear histology,” a research team led by Liam C. Macleod, MD, of the University of Washington in Seattle, concluded.

“We are hopeful this work may serve as an impetus to systematically improve implementation of histologically guided care for mRCC.”

Using the Surveillance, Epidemiology, and End Results (SEER) database, Dr. Macleod's group identified 14,521 patients diagnosed with mRCC from 1990 to 2009. They analyzed survival by treatment era (cytokine era, 1990–2005; targeted therapy era, 2006–2009).

Prior to the mid-2000s, the authors noted, mRCC treatments included the cytokines interferon alfa and interleukin-2. As a result of studies elucidating the molecular biology of kidney cancer, researchers developed agents targeting the vascular endothelial growth factor pathway (such as sunitinib, sorafenib, and bevacizumab) and the mammalian target of rapamycin pathway (such as temsirolimus and everolimus).

Results showed that median survival among the 4,149 patients with clear-cell mRCC improved significantly from 11 to 14 months before and after the debut of targeted therapy.

RELATED: Immunotherapy Combinations for Renal Cell Carcinoma Offer Promise, Challenges

Median survival improved significantly from 7 to 9 months among the 904 patients with non-clear-cell mRCC. Median survival did not change significantly among the 608 patients who had mRCC with sarcomatoid features and the 8,860 patients with RCC not otherwise specified.

Page 1 of 3

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs